Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Disproportionately Increasing Incidence of Inflammatory Bowel Disease in Female Patients and the Elderly: An Update Analysis from the Global Burden of Disease Study 2021
Danpanichkul, Pojsakorn , Duangsonk, Kwanjit , Ho, Agnes, Laoveeravat, Passisd , Vuthithammee, Chawinthorn , Dejvajara, Disatorn , Prasitsumrit, Vitchapong , Auttapracha, Thanida , Songtanin, Busara , Wetwittayakhlang, Panu , Kochhar, Gursimran , Ho, Agnes H Y , Lui, Rashid , Ng, Siew C , Farraye, Francis A , Wijarnpreecha, Karn , Danpanichkul, Pojsakorn , Ng, Siew C. , Farraye, Francis A. , Wijarnpreecha, Karn

American Journal of Gastroenterology | October 18, 2024 | Volume: 120 | Issue: 3 | Pages: 675-680

10.14309/ajg.0000000000003143 | PMID 39422305 Get It

INTRODUCTION: To update the global burden of inflammatory bowel disease (IBD) using data from the Global Burden of Disease 2021. METHODS: Data from Global Burden of Disease 2021 were analyzed to assess the IBD burden. RESULTS: In 2021, there were 375,140 new cases and 3.83 million total cases of IBD. Elderly onset IBD accounted for 11% of incidences. 167 countries increased IBD incidence rate, with rates rising in female patients (APC: +0.06%) and the elderly (APC: +0.14%) but stable in male patients and the overall population. DISCUSSION: Although the global burden of IBD has decreased overall, it has increased in female patients and the elderly.
Hydatid Cysts of the Psoas Muscle: Insights from the Past Five Years
Ciobotaru, Octavian Cătălin , Duca, Oana-Monica , Ciobotaru, Oana Roxana , Stamate, Elena , Piraianu, Alin Ionut , Dumitrascu, Adrian , Constantin, Georgiana Bianca , Matei, Madălina Nicoleta , Voinescu, Doina Carina, Luchian, S, Dumitrascu, Adrian George , Ciobotaru, Octavian Catalin , Ciobotaru, Oana Roxana

Life | October 18, 2024 | Volume: 14 | Issue: 10 | Pages: 1331

10.3390/life14101331 | PMID 39459631 Get It

Echinococcosis represents a major public health issue and continues to be endemic in various regions around the world. Hydatid cysts are commonly located in the liver (primary site), followed by the lungs (secondary site). However, they are also found in less typical organs such as the spleen, kidneys, peritoneum, retroperitoneum, pancreas, gallbladder, and various other organs, as well as in striate muscles. Hydatid cysts involving the psoas muscle are rare, and in the past five years, only a few articles have addressed this condition due to its low incidence. Symptoms can be quite vague, and serological testing might return negative, making imaging studies crucial for an accurate diagnosis. Treatment options involve surgery alongside antiparasitic agents. Despite having a low mortality rate, the recurrence of hydatid disease remains high. This paper aims to provide new clinical data through our case presentation, while also offering a review of the cases of hydatid cysts involving the psoas muscle that have been published over the past five years.
Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection
Metko, Muriel , Tonne, Jason M., Rios, Aleta , Thompson, Jill , Mudrick, Haley , Masopust, David , Díaz, Rosa María, Barry, Michael A. , Vile, Richard G. , Tonne, Jason , Veliz Rios, Alexa, Barry, Michael A , Masopust, David , Rios, Alexa Veliz

Vaccines | October 18, 2024 | Volume: 12 | Issue: 10 | Pages: 1191

10.3390/vaccines12101191 | PMID 39460356 Get It

Background: Long-lived, re-activatable immunity to SARS-CoV-2 and its emerging variants will rely on T cells recognizing conserved regions of viral proteins across strains. Heterologous prime–boost regimens can elicit elevated levels of circulating CD8+ T cells that provide a reservoir of first responders upon viral infection. Although most vaccines are currently delivered intramuscularly (IM), the initial site of infection is the nasal cavity. Methods: Here, we tested the hypothesis that a heterologous prime and boost vaccine regimen delivered intranasally (IN) will generate improved immune responses locally at the site of virus infection compared to intramuscular vaccine/booster regimens. Results: In a transgenic human ACE2 murine model, both a Spike-expressing single-cycle adenovirus (SC-Ad) and an IFNß safety-enhanced replication-competent Vesicular Stomatitis Virus (VSV) platform generated anti-Spike antibody and T-cell responses that diminished with age. Although SC-Ad-Spike boosted a prime with VSV-Spike-mIFNß, SC-Ad-Spike alone induced maximal levels of IgG, IgA, and CD8+ T-cell responses. Conclusions: There were significant differences in T-cell responses in spleens compared to lungs, and the intranasal boost was significantly superior to the intramuscular boost in generating sentinel immune effectors at the site of the virus encounter in the lungs. These data show that serious consideration should be given to intranasal boosting with anti-SARS-CoV-2 vaccines.
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj, Senthil , Patel, Shachi, McGarrah, Robert W. , Jones, Philip G. , Kwee, Lydia Coulter , Windsor, Sheryl L. , Ilkayeva, Olga , Muehlbauer, Michael J. , Newgard, Christopher B. , Kitzman, Dalane W. , Inzucchi, Silvio E. , Mentz, Robert J. , Kosiborod, Mikhail , Shah, Svati H. , Sauer, Andrew J , McGarrah, Robert , Jones, Philip G , Kwee, Lydia Coulter , Windsor, Sheryl L , Ilkayeva, Olga , Muehlbauer, Michael J , Newgard, Christopher B , Borlaug, Barry A , Kitzman, Dalane W , Shah, Sanjiv J , Margulies, Kenneth B. , Husain, Mansoor , Inzucchi, Silvio E , McGuire, Darren K , Lanfear, David E , Javaheri, Ali , Umpierrez, Guillermo E. , Mentz, Robert J , Sharma, Kavita , Kosiborod, Mikhail N , Shah, Svati , Borlaug, Barry A. , Husain, Mansoor , McGuire, Darren K. , Sharma, Kavita

Circulation: Heart Failure | October 18, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.124.011980 | PMID 39421941 Get It

BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar effects have not been observed in HF with preserved ejection fraction. We explore whether metabolic effects of SGLT2is vary across the left ventricular ejection fraction spectrum and their relationship with cardiometabolic end points in 2 randomized trials of dapagliflozin in HF. METHODS: Metabolomic profiling of 61 metabolites was performed in 527 participants from DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) and PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction HF; 12-week, placebo-controlled trials of dapagliflozin in HF with reduced ejection fraction and HF with preserved ejection fraction, respectively). Linear regression was used to assess changes in principal components analysis–defined metabolite factors with treatment from baseline to 12 weeks, as well as the relationship between changes in metabolite clusters and HF-related end points. RESULTS: The mean age was 66±11 years, 43% were female, and 33% were self-identified as Black. Two principal components analysis–derived metabolite factors (which were comprised of ketone and short-/medium-chain acylcarnitines) increased with dapagliflozin compared with placebo. Ketosis (defined as 3-hydroxybutyrate >500 μM) was achieved in 4.5% with dapagliflozin versus 1.2% with placebo ( P =0.03). There were no appreciable treatment effects on amino acids, including branched-chain amino acids. Increases in several acylcarnitines were consistent across LVEF ( P interaction >0.10), whereas the ketogenic effect diminished at higher LVEF ( P interaction =0.01 for 3-hydroxybutyrate). Increases in metabolites reflecting mitochondrial dysfunction (particularly long-chain acylcarnitines) and aromatic amino acids and decreases in branched-chain amino acids were associated with worse HF-related outcomes in the overall cohort, with consistency across treatment and LVEF. CONCLUSIONS: SGLT2is demonstrate common (fatty acid) and distinct (ketogenic) metabolic signatures across the LVEF spectrum. Changes in key pathways related to fatty acid and amino acid metabolism are associated with HF-related end points and may serve as therapeutic targets across HF subtypes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifiers: NCT03030235 and NCT02653482.
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis Data
Johnson, Andrew D., Szczepiorkowski, Zbigniew M. , Karam, Oliver , Nellis, Marianne E. , Schwartz, Joseph, Wu, Yanyun , Armendariz, Tomas , Burgstaler, Edwin A. , Collins, Laura , Geile, Kira, Pavenski, Katerina , Sanchez, Amber P. , Witt, Volker, Muthusamy, Amutha, Ramesh, Vidhyalakshmi , Thao, Mai See , Chlebeck, Therese M., Zantek, Nicole D. , Karam, Oliver , Armendariz, Tomas , Burgstaler, Edwin, Zantek, Nicole D , Balogun, Rasheed A. , Schneiderman, Jennifer , Winters, Jeffrey L. , Pavenski, Katerina , Pederson, Thomas

Journal of Clinical Apheresis | October 18, 2024 | Volume: 39 | Issue: 5 | Pages: No page available

10.1002/jca.22146 | PMID 39420527 Get It

ABSTRACTApheresis is performed worldwide for an increasing number of indications. The development of common data elements (CDE) for apheresis related areas may facilitate conduct of new research, enhance quality initiatives including benchmarking, and improve patient care. This report describes the systematic development of the Uniform Apheresis Case Report Form (UACRF) as part of the Apheresis in the United States (ApheresUS) program. A consensus panel of 17 diverse experts in apheresis, related specialties, and electronic case report form (eCRF), and database development was assembled. The panel met via online conferencing from November 17, 2020 to December 1, 2021. A draft document was posted online for public comment from October 11, 2021 to November 10, 2021. Feedback was collected using an online survey tool. The consensus panel revised the UACRF. This version was converted to an eCRF with additional changes made to improve usability in this format. The final version of the UACRF was created on August 24, 2023. The UACRF contains 16 modules: procedure and subject eligibility, patient demographics, general procedure information, laboratory parameters, vascular access, common procedure elements, eight procedure specific modules (mononuclear cell collection and seven therapeutic modalities), outcomes, and site information. A total of 137 data elements were created, including 57 with one or more subelements. The UACRF is the first systematic attempt to develop CDE for therapeutic apheresis and white blood cell collections. Further validation of the UACRF is necessary to confirm the tool's ability to collect the relevant data elements and determine the usability of the form.
Barriers to global engagement for African researchers: A position paper from the Alliance for Medical Research in Africa (AMedRA)
Gaye, Bamba , Singh, Gurbinder , Gaye, Ngone Diaba, Ka, Mame Madjiguène , Seck, Daouda, Gueye, Khadidiatou, Kitara, David Lagoro , Lassale, Camille , Anne, Malick, Diaw, Mor , Gaye, Magaye, Fall, Abdou Salam , Diongue, Aïda, Seck, Ibrahima , Belkhadir, Jamal , Wone, I, Gueye, Sérigne Maguèye , Sow, Papa Salif , Kohen, Jamal Eddine, Vogelsang, Dorothea, Mbaye, Maïmouna Ndour, Liyong, Elisabeth Alice, Kengne, André Pascal , Sougou, Ndèye Mariéme, Ba, Awa, Tukakira, John, Lorenz, Thiess , Kabore, Elisé , Muzumala, Malaizyo Gabriel, Olanrewaju, A. I., Jaiteh, Lamin , Délicat-Loembet, Lucrèce M. , Alson, Aimée Olivat Rakoto, Niang, Khadim, Mwebaze, Ernest , Nakatumba‐Nabende, Joyce , Machuve, Dina , Adie, Prestone, Hanne, Fatoumata, Sougou, Marième, Koffi, Kouassi Gustave, Luwanda, Lameck, Mekonnen, Demeke, Ebeid, Fatma Soliman Elsayed , Enama, Jean Paul, Zeba, Mohamadi , Guedou, Fernand Aimé, Mbélesso, Pascal , Carter, Jennifer , Coulibaly, Bakary, Dramé, Mohamed Lamine, Mouanga, Alain Maxime , Lacroix, Philippe, Diagana, Mouhamadou , Ekouévi, Didier Koumavi , Houinato, Dismand, Faye, Adama , Wambugu, Vivien , Kamaté, Jean, Lalika, Mathias , Ale, Boni Maxime , Fall, Ibrahima Socé , Samb, Abdoulaye, Jobe, Modou , Isiozor, Nzechukwu Michael , Gaye, Ngone Diaba, Seck, Daouda , Seck, Sidy Mohamed , Sow, Abdourahmane , Diongue, Aïda, Lamptey, Roberta , Sobngwi, Eugène , Muzumala, Malaizyo G. , Maina, Ciira wa , Adie, Prestone, Tine, Roger Clément Kouly , Koffi, K. G. , Sattler, Elisabeth Lilian Pia , Enama, Jean-Paul, Coulibaly, Bakary, Preux, Pierre‐Marie , Nsoesie, Elaine Okanyene , Tshilolo, Léon Muepu

Journal of Global Health | October 18, 2024 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7189/jogh.14.03042 | PMID 39421942 Get It

Transcranial doppler (TCD) in predicting outcomes following successful mechanical thrombectomy of large vessel occlusions in anterior circulation: a systematic review and meta-analysis
Jazayeri, Seyed Behnam , Pirahanchi, Yasaman , Ravi, Vikas , Carrión‐Penagos, Julián , Bowers, Jeffrey, Modir, Royya , Agrawal, Kunal , Hemmen, Thomas , Meyer, Brett C. , Meyer, Dawn , Sabayan, Behnam , Bowers, Jeffrey, Agrawal, Kunal, Shahripour, Reza Bavarsad , Agrawal, Kush

Journal of NeuroInterventional Surgery | October 18, 2024 | Volume: 17 | Issue: 12 | Pages: 1325-1332

10.1136/jnis-2024-022457 | PMID 39424305 Get It

Background Transcranial Doppler (TCD) is a non-invasive, bedside tool that allows for real-time monitoring of the patient’s hemodynamic status following mechanical thrombectomy (MT). This systematic review and meta-analysis aims to evaluate the predictive value of TCD parameters following successful MT (Thrombolysis in Cerebral Infarction 2b–3). Methods In July 2024, we searched PubMed, Embase, and Scopus, to identify observational studies in which TCD parameters were measured within 48 hours of MT. Using random-effects models, we compared four TCD parameters (mean flow velocity (MFV), MFV index, pulsatility index (PI), and peak systolic velocity (PSV) among groups with vs without hemorrhagic transformation (HT) and favorable vs poor functional recovery (modified Rankin Scale 0–2 vs 3–6). Results Eleven studies comprising 1432 patients (59% male; mean age range: 63–73 years) were included. The MFV and MFV index were higher in patients with HT (Hedges' g=0.42 and 0.54, P=0.015 and 0.005, respectively). Patients with MFV index ≥1.3 showed a higher risk of all HT (RR 1.97; 95% confidence interval (CI) 1.28 to 3.03, P=0.002), symptomatic HT (RR 4.68; 95% CI 1.49 to 14.65, P=0.008), and poor functional status at 90 days (RR 1.65; 95% CI 1.27 to 2.14, P=0.029), respectively. There was no difference in mean PSV (P=0.1) and PI (P=0.3) among groups with and without HT. Conclusion This study underscores the prognostic value of the MFV index in predicting HT, symptomatic HT, and poor functional recovery after successful MT in the anterior circulation. Large-scale, multi-center studies are necessary to confirm these findings and to validate the MFV index as a reliable predictor for improving post-thrombectomy care.
Neuropalliative Care
Robinson, Maisha T. , Creutzfeldt, Claire J.

Seminars in Neurology | October 17, 2024 | Volume: 44 | Issue: 05 | Pages: 483-483

10.1055/s-0044-1790587 | PMID 39419040 Get It

EUS–guided therapies for primary and secondary prophylaxis in gastric varices—An updated systematic review and meta-analysis
Nguyen, Andrew K. L., Deliwala, Smit , Ramai, Daryl , Kassab, Lena L., Muthusamy, Arunkumar, Kamal, Faisal, Adler, Douglas G., Chandan, Saurabh , Nguyen, Andrew Khoi, Mohan, Babu P. , Facciorusso, Antonio , Bilal, Mohammad , Samanta, Jayanta

Endoscopic Ultrasound | October 17, 2024 | Volume: 12 | Issue: 4 | Pages: 351-361

10.1097/eus.0000000000000017 | PMID 37795350 Get It

Abstract Background and Objectives Gastric varices (GVs) are associated with a higher risk of uncontrolled bleeding and death when compared with esophageal varices. While endoscopic glue injection therapy has been traditionally used for secondary prophylaxis in GV, data regarding primary prophylaxis continue to emerge. Recently, EUS–guided therapies have been used in GV bleeding. Methods We conducted a comprehensive search of several major databases from inception to June 2022. Our primary goals were to estimate the pooled rates of treatment efficacy, GV obliteration, GV recurrence, and rebleeding with EUS-guided therapy in primary and secondary prophylaxis. Overall adverse events and technical failures were assessed. Random-effects model was used for our meta-analysis, and heterogeneity was assessed using the I 2 % statistics. Results Eighteen studies with 604 patients were included. In primary prophylaxis, pooled rate of GV obliteration was 90.2% (confidence interval [CI], 81.1–95.2; I 2 = 0). With combination EUS–glue and coil therapy, the rate was 95.4% (CI, 86.7%–98.5%; I 2 = 0). Pooled rate of posttherapy GV bleeding was 4.9% (CI, 1.8%–12.4%; I 2 = 0). In secondary prophylaxis, pooled rate of treatment efficacy was 91.9% (CI, 86.8%–95.2%; I 2 = 12). With EUS-glue, EUS-coil, and combination EUS–glue and coil, the rates were 94.3% (CI, 88.9%–97.1%; I 2 = 0), 95.5% (CI, 80.3%–99.1%; I 2 = 0), and 88.7% (CI, 76%–95.1%; I 2 = 14), respectively. Pooled rate of GV obliteration was 83.6% (CI, 71.5%–91.2%; I 2 = 74). With EUS-glue, EUS-coil, and combination EUS–glue and coil, the rates were 84.6% (CI, 75.9%–90.6%; I 2 = 31), 92.3% (CI, 81.1%–97.1%; I 2 = 0), and 84.5% (CI, 50.8%–96.7%; I 2 = 75), respectively. Pooled rates of GV rebleeding and recurrence were 18.1% (CI, 13.1%–24.3%; I 2 = 16) and 20.6% (CI, 9.3%–39.5%; I 2 = 66), respectively. Conclusion Our analysis shows that EUS-guided therapy for GVs is technically feasible and clinically successful in both primary and secondary prophylaxis of GV.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Aldoss, Ibrahim , Kopmar, Noam E. , Lin, Chenyu , Dekker, Simone E. , Gupta, Vishal, O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Kate , Ahmed, Mohamed , Schwartz, Marc S. , Tracy, Sean , Mukherjee, Akash , Ladha, Abdullah , Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Pullarkat, Vinod , Muffly, Lori , Oliai, Caspian , Yaghmour, George , Sutherland, Katherine, Zambrano, Héctor, Bradshaw, Danielle , Kubiak, Michal , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Stefan, Maryann, O'Dwyer, Kristen M., Blunk, Betsy, Bishop, Michael R. , Aldoss, Ibrahim , Kopmar, Noam E , Lin, Chenyu , Gupta, Vishal K , Muhsen, Ibrahim N , Valtis, Yannis , Miller, Katharine , Chen, Evan , Mercadal, Santiago , Tracy, Sean I , Dholaria, Bhagirathbhai R , Battiwalla, Minoo , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Solh, Melham M , Kota, Vamsi , Frey, Noelle V , Park, Jae H , Luskin, Marlise R , Stock, Wendy , Cassaday, Ryan D , Muffly, Lori , Bachanova, Veronika , Roloff, Gregory W. , Ahmed, Naveed, Dykes, Kaitlyn C. , Schwartz, Marc, Dholaria, Bhagirathbhai , Battiwalla, Minoo , Hilal, Talal , Tsai, Stephanie B., Kota, Vamsi , Leonard, Jessica T , Frey, Noelle V. , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal , Faramand, Rawan , Oliai, Caspian H , Majhail, Navneet S. , Mathews, John Abraham , Advani, Anjali S. , O'Dwyer, Kristin , Lee, Catherine J , Bishop, Michael Russell

Journal of Clinical Oncology | October 17, 2024 | Volume: 43 | Issue: 5 | Pages: 558-566

10.1200/jco.24.00321 | PMID 39418622 Get It

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.